Measles vaccination: New strategies and formulations

Expert Review of Vaccines

Volumn 7, Issue 8, 2008, Pages 1215-1223

  De Vries, Rory D ^a   Stittelaar, Koert J ^b   Osterhaus, Albert D M E ^a   De Swart, Rik L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ViroClinics Biosciences BV   (Netherlands)

Author keywords

Aerosol; Attenuated; DNA; Measles; Vaccine; Vector; Virus

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; MEASLES VACCINE; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; CHILDHOOD MORTALITY; CLINICAL TRIAL; GENE GUN; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MEASLES; MEASLES VACCINATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

HUMANS; MEASLES; MEASLES VACCINE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 53849093466     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.8.1215     Document Type: Review

References (100)

1. Rauh LW, Schmidt R. Measles immunization with killed virus vaccine. Am. J. Dis. Child. 109, 232-237 (1965).
2. Polack FP, Auwaerter PG, Lee SH et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5, 629-634 (1999).
3. Fulginiti VA, Eller JJ, Downte AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202, 1075-1080 (1967).
4. Nader PR, Horwitz MS, Rousseau J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72, 22-28 (1968).
5. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9, 1209-1213 (2003).
6. WHO. Measles vaccines. Wkly Epidemiol. Rec. 79, 130-142 (2004).
7. Katz SL. Immunization with live attenuated measles virus vaccines: five years' experience. Arch. Gesamte Virusforsch. 16, 222-230 (1965).
8. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr. Top. Microbiol. Immunol. 191, 13-33 (1995).
9. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull. World Health Organ. 81, 61-70 (2003).
10. De Quadros CA, Olive JM, Hersh BS et al. Measles elimination in the Americas. Evolving strategies. JAMA 275, 224-229 (1996).
11. Henao-Restrepo AM, Strebel P, Hoekstra E.J., Birmingham M, Bilous J. Experience in global measles control, 1990-2001. J. Infect. Dis. 187(Suppl. 1), S15-S21 (2003).
12. Otten M, Kezaala R, Fall A et al. Public-health impact of accelerated measles control in the WHO African region 2000-03. Lancet 366, 832-839 (2005).
13. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369, 191-200 (2007).
14. Angel JB, Walpita P, Lerch RA et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann. Intern. Med. 129, 104-106 (1998).
15. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22, 1914-1920 (2004).
16. Dhiman N, Ovsyannikova IG, Cunningham JM et al. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J. Infect. Dis. 195, 21-29 (2007).
17. Dhiman N, Poland GA, Cunningham JM et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J. Allergy Clin. Immunol. 120, 666-672 (2007).
18. Dhiman N, Ovsyannikova IG, Vierkant RA et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26, 1731-1736 (2008).
19. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 25, 6296-6304 (2007).
20. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91, 715-718 (1977).
21. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280, 527-532 (1998).
22. Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 23, 95-106 (1995).
23. Diaz-Ortega JL, Forsey T, Clements CJ, Milstien J. The relationship between dose and response of standard measles vaccines. Biologicals 22, 35-44 (1994).
24. Garenne M, Leroy O, Beau J-P, Sene I. Child mortality after high-titre measles vaccines:prospective study in Senegal. Lancet 338, 903-907 (1991).
25. Holt EA, Moulton LH, Siberry GK, Halsey NA. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168, 1087-1096 (1993).
26. Knudsen KM, Aaby P, Whittle H et al. Child mortality following standard, medium or high titre measles immunization in West Africa. Int. J. Epidemiol. 25, 665-673 (1996).
27. Aaby P, Jensen H, Samb B et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 361, 2183-2188 (2003).
28. Sabin AB, Flores Arechiga A, Fernandez de Castro J et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 249, 2651-2662 (1983).
29. Valdespino-Gomez JL, De Lourdes Garcia-Garcia M, Fernandez de Castro J, Henao-Restrepo AM, Bennett J, Sepulveda-Amor J. Measles aerosol vaccination. Curr. Top. Microbiol. Immunol. 304, 165-193 (2006). • Good review for those interested in the history of measles vaccination via the respiratory route.
30. LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 17, 1796-1803 (1999).
31. Sabin AB, Fernandez de Castro J, Flores Arechiga A, Sever JL, Madden DL, Shekarchi I. Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet 320, 604 (1982).
32. Sabin AB, Flores Arechiga A, Fernandez de Castro J, Albrecht P, Sever JL, Shekarchi I. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 251, 2363-2371 (1984).
33. Fernandez de Castro J, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. La vacunación antisarampionosa en México por el método de aerosol. Salud Publica Mex. 39, 53-60 (1997).
34. Whittle HC, Rowland MG, Mann GF, Lamb WH, Lewis RA. Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 324, 834-837 (1984).
35. Fernandez de Castro J, Valdespino-Gomez JL, Diaz-Ortega JL, Zarate-Aquino ML. Diploid cell measles vaccine. JAMA 256, 714-714 (1986).
36. Khanum S, Uddin N, Garelick H, Mann G, Tomkins A. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1(8525), 150-153 (1987).
37. Ekunwe EO. Immunization by inhalation of aerosolized measles vaccine. Ann. Trop. Paediatr. 10, 145-149 (1990).
38. Wong-Chew RM, Islas-Romero R, De Lourdes Garcia-Garcia M et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J. Infect. Dis. 189, 254-257 (2004).
39. Wong-Chew RM, Islas-Romero R, De Lourdes Garcia-Garcia M et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 24, 683-690 (2006).
40. Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum. Vaccines 1, 30-36 (2005).
41. Low N, Kraemer S, Schneider M, Henao-Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26, 383-398 (2008).
42. Bellanti JA, Zeligs BJ, Mendez-Inocencio J et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 22, 1214-1220 (2004).
43. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull. World Health Organ. 80, 806-812 (2002).
44. Dilraj A, Cutts FT, Fernandez de Castro J et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355, 798-803 (2000).
45. Dilraj A, Cutts FT, Bennett JV et al. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr. Infect. Dis. J. 19, 1211-1213 (2000).
46. Sepulveda-Amor J, Valdespino-Gomez JL, De Lourdes Garcia-Garcia M et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 20, 2790-2795 (2002).
47. Fernandez de Castro J, Bennett JV, Rincon HG, Munoz MT, Sanchez LA, Santos JI. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine 23, 1079-1084 (2005).
48. Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 25(21), 4170-4174 (2007). • Authors resample of South African school children included in their original study [44,45] to address longevity of the induced immune responses.
49. De Swart RL, Kuiken T, Fernandez de Castro J et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24, 6424-6436 (2006).
50. De Swart RL, LiCalsi C, Quirk AV et al. Measles vaccination of macaques by dry powder inhalation. Vaccine 25, 1183-1190 (2007).
51. Burger JL, Cape SP, Braun CS et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J. Aerosol Med. Pulm. Drug. Deliv. 21(1), 25-34 (2007).
52. Stittelaar KJ, De Swart RL, Osterhaus ADME. Vaccination against measles: a neverending story. Expert Rev. Vaccines 1, 151-159 (2002).
53. Premenko-Lanier M, Rota P, Rhodes G, Bellini W, McChesney M. Prior DNA vaccination does not interfere with the live-attenuated measles vaccine. Vaccine 22, 762-765 (2004).
54. Cardoso AI, Blixenkrone-Möller M, Fayolle J, Liu M, Buckland R, Wild TF. Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity. Virology 225, 293-299 (1996).
55. Fooks AR, Jeevarajah D, Warnes A, Wilkinson GW, Clegg JC. Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene. Viral Immunol. 9, 65-71 (1996).
56. Yang K, Mustafa F, Valsamakis A, Santoro JC, Griffin DE, Robinson HL. Early studies on DNA-based immunizations for measles virus. Vaccine 15, 888-891 (1997).
57. Schlereth B, Germann P-G, Ter Meulen V, Niewiesk S. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J. Gen. Virol. 81, 1321-1325 (2000).
58. Polack FP, Lee SH, Permar S et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6, 776-781 (2000).
59. Polack FP, Hoffman SJ, Moss WJ, Griffin DE. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J. Infect. Dis. 187, 1794-1800 (2003).
60. Premenko-Lanier M, Rota PA, Rhodes G et al. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 307, 67-75 (2003).
61. Premenko-Lanier M, Rota PA, Rhodes GH, Bellini WJ, McChesney MB. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J. Infect. Dis. 189, 2064-2071 (2004).
62. Polo JM, Gardner JP, Ji Y et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) 104, 181-185 (2000).
63. Leitner WW, Hwang LN, deVeer MJ et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9, 33-39 (2003).
64. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4, 553-564 (2004).
65. Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22, 1537-1544 (2004).
66. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 189, 821-829 (1999).
67. Kirman JR, Turon T, Su H et al. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 71, 575-579 (2003).
68. Song MK, Vindurampulle CJ, Capozzo AV et al. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J. Virol. 79, 9854-9861 (2005).
69. Capozzo AV, Ramirez K, Polo JM et al. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J. Immunol. 176, 5671-5681 (2006).
70. Pasetti MF, Resendiz-Albor A, Ramirez K et al. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin. Pharmacol. Ther. 82, 672-685 (2007).
71. Ramirez K, Barry EM, Ulmer J et al. Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen. Hum. Gene Ther. 19, 522-531 (2008).
72. Denis-Mize KS, Dupuis M, Singh M et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell. Immunol. 225, 12-20 (2003).
73. Pan CH, Nair N, Adams RJ et al. Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin. Vaccine Immunol. 15, 697-706 (2008).
74. Pan CH, Jimenez GS, Nair N et al. Vaxfectin-formulated measles DNA vaccine encoding the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. Clin. Vaccine Immunol. 15, 1214-1221 (2008). • First study in which DNA vaccination using plasmids expressing measles virus-fusion and -hemagglutinin protein induces good virus-neutralizing antibody responses. If these data can be reproduced and the adjuvant proves to be safe for human use, this could be a candidate for evaluation in clinical trials in humans.
75. Stittelaar KJ, Wyatt LS, De Swart RL et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74, 4236-4243 (2000).
76. Zhu Y-D, Rota P, Wyatt LS et al. Evaluation of recombinant vaccinia virus - measles vaccines in infant rhesus macaques with pre-existing measles antibody. Virology 276, 202-213 (2000).
77. Schlereth B, Buonocore L, Tietz A, Meulen V et al. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J. Gen. Virol. 84, 2145-2151 (2003).
78. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol. 77, 5209-5217 (2003).
79. Huang Z, Dry I, Webster D, Strugnell R, Wesselingh S. Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 19, 2163-2171 (2001).
80. Marquet-Blouin E, Bouche FB, Steinmetz A, Muller CP. Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin. Plant Mol. Biol. 51, 459-469 (2003).
81. Webster DE, Smith SD, Pickering RJ et al. Measles virus hemagglutinin protein expressed in transgenic lettuce induces neutralising antibodies in mice following mucosal vaccination. Vaccine 24, 3538-3544 (2006).
82. Webster DE, Thomas MC, Huang Z, Wesselingh SL. The development of a plant-based vaccine for measles. Vaccine 23, 1859-1865 (2005).
83. Webster DE, Cooney ML, Huang Z et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol. 76, 7910-7912 (2002).
84. Lowell GH, Smith LF, Seid RC, Zollinger WD. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J. Exp. Med. 167, 658-663 (1988).
85. Chabot S, Brewer A, Lowell G et al. A novel intranasal protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23, 1374-1383 (2005).
86. Taylor J, Pincus S, Tartaglia J et al. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J. Virol. 65, 4263-4274 (1991).
87. Wild TF, Bernard A, Spehner D, Villeval D, Drillien R. Vaccination of mice against canine distemper virus-induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper virus antigens. Vaccine 11, 438-444 (1993).
88. Osterhaus ADME. Catastrophes after crossing species barriers. Philos. Trans. R. Soc. Lond. B 356, 791-793 (2001).
89. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J. Virol. 73, 4823-4828 (1999).
90. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert. Rev. Vaccines 6, 255-266 (2007). • Good review of current use of viral vectors, including measles virus, for the development of vaccines.
91. Zuniga A, Wang Z, Liniger M et al. Attenuated measles virus as a vaccine vector. Vaccine 25, 2974-2983 (2007).
92. Lorin C, Mollet L, Delebecque F et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78, 146-157 (2004).
93. Lorin C, Delebecque F, Labrousse V et al. A recombinant live attenuated measles vaccine vector primes effective HLAA0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23, 4463-4472 (2005).
94. Reyes del Valle J, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles challenge. J. Virol. 81, 10597-10605 (2007).
95. Brandler S, Lucas-Hourani M, Moris A et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS. Negl. Trop. Dis. 1, E96 (2007).
96. Liniger M, Zuniga A, Tamin A et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26, 2164-2174 (2008).
97. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191, 207-214 (2005).
98. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J. Infect. Dis. 189, S27-S35 (2004).
99. De Quadros CA, Andrus JK, Danovaro-Holliday MC, Castillo-Solorzano C. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev. Vaccines 7, 355-362 (2008).
100. Premenko-Lanier M, Hodge G, Rota P, Tamin A, Bellini W, McChesney M. Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350, 429-432 (2006).